Oxford BioMedica PLC (OXBDF)

[marcusl2]

Digital tech from Autolus and Oxford BioMedica to speed advanced therapies
UK funds efforts to make country a leader in cell and gene therapy

Also receiving funding is Oxford BioMedica, one of the UK’s leading manufacturers of cell and gene therapies, best know for supplying the lentiviral vector used in Novartis’ CAR-T therapy Kymriah.

The three companies will share a £4.3m Digitalisation of Medicines Manufacturing fund from the government Department for Business, Enterprise and Industrial Strategy, (BEIS) which aims to create more efficient and innovative methods for manufacturing medicines.

Oxford Biomedica will look to dramatically reduce the supply time for manufacturing by using a new digital and robotics framework to increase capacity, reduce waste and cut costs.

HTTp://www.pmlive.com/pharma_news/digital_tech_from_autolous_and_oxford_biomedica_to_speed_advanced_therapies_1262473